SCHEMBL950182

SCHEMBL950182

N#Cc1cccc(NCc2ccc3c(c2)OCCO3)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
RAB9A P51151 2/20 0.61
NPC1 O15118 1/20 0.61
NFKB1 P19838 1/20 0.61
NFKB2 Q00653 1/20 0.61
RELA Q04206 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
NOS1 P29475 1/20 0.53
GAA P10253 3/20 0.49
PDE5A O76074 2/20 0.47
EGFR P00533 3/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
VNN1 O95497 1/20 0.47
HDAC4 P56524 1/20 0.46
MEF2D Q14814 1/20 0.46
TGFBR1 P36897 1/20 0.45
PKM P14618 1/20 0.44
GSK3A P49840 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL951028 0.82 VNN1 (0.45) ALDH1A1RAB9ANPC1NFKB1NFKB2
SCHEMBL956024 0.77 PDE5A (0.48) ALDH1A1RAB9ANPC1NFKB1NFKB2
SCHEMBL6691560 0.77 NOS1 (0.58) ALDH1A1NOS1HDAC1HDAC8HDAC6
SCHEMBL1680823 0.75 LMNA (0.57) ALDH1A1NOS1HDAC1HDAC8HDAC6
SCHEMBL11234801 0.71 INSR (0.57) ALDH1A1RAB9ANPC1SMN1; SMN2GAA
SCHEMBL13605307 0.71 MAPT (0.59) ALDH1A1RAB9ANPC1SMN1; SMN2GAA
SCHEMBL934511 0.71 VNN1 (0.58) ALDH1A1RAB9ANPC1SMN1; SMN2NOS1
SCHEMBL9672474 0.71 MAPT (0.63) ALDH1A1RAB9ANPC1SMN1; SMN2GAA
SCHEMBL5333927 0.71 GAA (0.72) ALDH1A1RAB9ANPC1NFKB1NFKB2
SCHEMBL943860 0.71 PKM (0.54) ALDH1A1RAB9ANPC1NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454243-A2 TETRAZOLE DERIVATIVES Merck Serono SA (CH) 2012-05-23 EP disclosed
US-20120115869-A1 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2012-05-10 US disclosed
US-20120115869-A1 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2012-05-10 US disclosed
US-20120115869-A1 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2012-05-10 US disclosed
WO-2011006935-A2 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2011-01-20 WO disclosed
WO-2011006935-A2 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115869-A1 TETRAZOLE DERIVATIVES TSLP, IL5, CMA1 ALDH1A1 184/4885RAB9A 2889/4885NPC1 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.